{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:37:23Z","timestamp":1685594243565},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Therapieentscheidung Neben der Wirksamkeit spielen individuelle\n      Therapieziele, Komorbidit\u00e4ten, Komedikationen und auch Compliance-Themen eine zunehmende Rolle\n      bei der Auswahl des individuell zu pr\u00e4ferierenden Tyrosinkinase-Inhibitors (TKI).<\/jats:p><jats:p>\n            Nebenwirkungen Hier gilt es, die sog. Klasseneffekte (ein Effekt,\n      der unter allen TKIs bei einer bestimmten Klasse von TKIs auftreten kann) von den\n      substanzspezifischen Nebenwirkungen der einzelnen TKIs zu unterscheiden.<\/jats:p><jats:p>\n            Was tun bei Nebenwirkungen und Unvertr\u00e4glichkeit? In Studien\n      konnte gezeigt werden, dass durch Anpassung der Dosis des TKIs (ggf. auch mit zeitlich\n      begrenzter Therapiepause) und\/oder \u00c4nderung der Begleitmedikation eine Verbesserung der\n      Therapietreue (Adh\u00e4renz) in den meisten F\u00e4llen erreicht werden konnte.<\/jats:p><jats:p>\n            Wie k\u00f6nnen TKI-Nebenwirkungen vermieden werden? Zur Evaluation\n      der Belastungen und Einschr\u00e4nkungen ist eine gute Arzt-Patienten-Interaktion entscheidend.\n      Hiermit wird das Therapieziel einer guten Wirksamkeit und Adh\u00e4renz am ehesten erreicht.<\/jats:p>","DOI":"10.1055\/a-1941-7438","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T22:46:05Z","timestamp":1685573165000},"page":"744-751","source":"Crossref","is-referenced-by-count":0,"title":["Chronisch myeloische Leuk\u00e4mie"],"prefix":"10.1055","volume":"148","author":[{"given":"Martina","family":"Crysandt","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie, Onkologie, H\u00e4mostaseologie und Stammzelltransplantation, Uniklinik RWTH Aachen, Aachen, Deutschland"},{"name":"Standort Aachen, Centrum f\u00fcr Integrierte Onkologie Aachen, Bonn, K\u00f6ln, D\u00fcsseldorf (CIO ABCD), aachen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie, Onkologie, H\u00e4mostaseologie und Stammzelltransplantation, Uniklinik RWTH Aachen, Aachen, Deutschland"},{"name":"Standort Aachen, Centrum f\u00fcr Integrierte Onkologie Aachen, Bonn, K\u00f6ln, D\u00fcsseldorf (CIO ABCD), aachen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence\n          Blood","volume":"129","author":"TL Holyoake","year":"2017"},{"issue":"10","key":"ref2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"A Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"01","key":"ref3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","article-title":"Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase:\n          results from the European ENEST1st study","volume":"30","author":"A Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"07","key":"ref4","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid\n          leukemia: final results from the BFORE trial Leukemia","volume":"36","author":"TH Br\u00fcmmendorf","year":"2022"},{"issue":"05","key":"ref5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia:\n          2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"HM Kantarjian","year":"2012","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic\n          myelogenous leukemia","volume":"11","author":"S Balabanov","year":"2014","journal-title":"Drug Discov Today Technol"},{"issue":"03","key":"ref7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/17474086.2021.1886918","article-title":"Optimizing health-related quality of life in patients with chronic myeloid\n          leukemia treated with tyrosine kinase inhibitors","volume":"14","author":"F Efficace","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"04","key":"ref8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3324\/haematol.2022.280922","article-title":"Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid\n          leukemia by IKK2-inhibition","volume":"108","author":"M B\u00fctow","year":"2022","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia\n          \u2013 What to look for when treatment-free remission is not an option","volume":"56","author":"JH Lipton","year":"2022","journal-title":"Blood Rev"},{"issue":"02","key":"ref10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed\n          chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"HM Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"ref11","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in\n          Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"JE Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic\n          myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd\n          trial","volume":"30","author":"A Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"04","key":"ref13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic\n          myeloid leukemia therapy: a review","volume":"477","author":"V Kumar","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11239-018-1792-1","article-title":"Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia","volume":"47","author":"CL Wang","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"01","key":"ref15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid\n          leukemia: results of the randomized CML study IV","volume":"126","author":"S Saussele","year":"2015","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia,\n          as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant\n          forms of BCR-ABL1 kinase","volume":"98","author":"PW Manley","year":"2020","journal-title":"Leuk Res"},{"issue":"03","key":"ref17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously\n          treated with at least two tyrosine kinase inhibitors: longer-term follow-up of\n          ASCEMBL","volume":"37","author":"A Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"06","key":"ref18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s12185-022-03314-y","article-title":"Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic\n          myeloid leukemia: a pooled analysis","volume":"115","author":"N Takahashi","year":"2022","journal-title":"Int J Hematol"},{"issue":"03","key":"ref19","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/cam4.5212","article-title":"Asciminib vs bosutinib in CML patients pretreated with \u22652 tyrosine kinase\n          inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study","volume":"12","author":"J Yuda","year":"2023","journal-title":"Cancer Med"},{"issue":"S 01","key":"ref21","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1182\/blood-2021-151240","article-title":"ASH 2021: #3608","volume":"138","author":"S Isfort","year":"2021"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40164-018-0101-1","article-title":"Correlation of plasma concentration and adverse effects of bosutinib: standard\n          dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid\n          leukemia","volume":"7","author":"A Mita","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"21","key":"ref23","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082.","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a\n          randomized, open-label phase 2 clinical trial","volume":"138","author":"J Cortes","year":"2021","journal-title":"Blood"},{"issue":"10","key":"ref24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00277-013-1769-2","article-title":"Improved tolerability by a modified intermittent treatment schedule of dasatinib\n          for patients with chronic myeloid leukemia resistant or intolerant to imatinib","volume":"92","author":"P La Ros\u00e9e","year":"2013","journal-title":"Ann Hematol"},{"issue":"08","key":"ref25","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: the patient perspective and\n          areas of unmet needs","volume":"34","author":"G Sharf","year":"2020","journal-title":"Leukemia"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1941-7438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T22:49:47Z","timestamp":1685573387000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1941-7438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,5,31]]},"published-print":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1941-7438","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}